Terms: = Lymphoma AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027
18 results:
1. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Al-Kali A; Aldoss I; Atherton PJ; Strand CA; Shah B; Webster J; Bhatnagar B; Flatten KS; Peterson KL; Schneider PA; Buhrow SA; Kong J; Reid JM; Adjei AA; Kaufmann SH
Cancer Med; 2023 Dec; 12(23):21229-21239. PubMed ID: 37960985
[TBL] [Abstract] [Full Text] [Related]
2. Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor.
De Pascale M; Bissegger L; Tarantelli C; Beaufils F; Prescimone A; Mohamed Seid Hedad H; Kayali O; Orbegozo C; Raguž L; Schaefer T; Hebeisen P; Bertoni F; Wymann MP; Borsari C
Eur J Med Chem; 2023 Feb; 248():115038. PubMed ID: 36634458
[TBL] [Abstract] [Full Text] [Related]
3. A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Collins GP; Clevenger TN; Burke KA; Yang B; MacDonald A; Cunningham D; Fox CP; Goy A; Gribben J; Nowakowski GS; Roschewski M; Vose JM; Vallurupalli A; Cheung J; Raymond A; Nuttall B; Stetson D; Dougherty BA; Schalkwijk S; Carnevalli LS; Willis B; Tao L; Harrington EA; Hamdy A; Izumi R; Pease JE; Frigault MM; Flinn I
Leuk Lymphoma; 2021 Nov; 62(11):2625-2636. PubMed ID: 34269152
[TBL] [Abstract] [Full Text] [Related]
4.
Pan R; Wang Z; Wang X; Fang R; Xia Q; Rao Q
Int J Surg Pathol; 2022 Feb; 30(1):99-105. PubMed ID: 34057377
[TBL] [Abstract] [Full Text] [Related]
5. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with lymphoma?
Tarantelli C; Lupia A; Stathis A; Bertoni F
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033478
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell lymphoma.
Bresin A; Cristofoletti C; Caprini E; Cantonetti M; Monopoli A; Russo G; Narducci MG
J Invest Dermatol; 2020 May; 140(5):1045-1053.e6. PubMed ID: 31682844
[TBL] [Abstract] [Full Text] [Related]
7. A phase II study to assess the safety and efficacy of the dual mtorc1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
[TBL] [Abstract] [Full Text] [Related]
8. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
[TBL] [Abstract] [Full Text] [Related]
9. TAK-228 (formerly MLN0128), an investigational oral dual torc1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Ghobrial IM; Siegel DS; Vij R; Berdeja JG; Richardson PG; Neuwirth R; Patel CG; Zohren F; Wolf JL
Am J Hematol; 2016 Jun; 91(4):400-5. PubMed ID: 26800393
[TBL] [Abstract] [Full Text] [Related]
10. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
[TBL] [Abstract] [Full Text] [Related]
11. torc1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
Simmons JK; Patel J; Michalowski A; Zhang S; Wei BR; Sullivan P; Gamache B; Felsenstein K; Kuehl WM; Simpson RM; Zingone A; Landgren O; Mock BA
Mol Oncol; 2014 Mar; 8(2):261-72. PubMed ID: 24429254
[TBL] [Abstract] [Full Text] [Related]
12. Mechanisms of activity of the torc1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
[TBL] [Abstract] [Full Text] [Related]
13. Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets.
Dal Col J; Mastorci K; Faè DA; Muraro E; Martorelli D; Inghirami G; Dolcetti R
Cancer Res; 2012 Apr; 72(7):1825-35. PubMed ID: 22311672
[TBL] [Abstract] [Full Text] [Related]
14. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
Gera J; Lichtenstein A
Leuk Lymphoma; 2011 Oct; 52(10):1857-66. PubMed ID: 21599581
[TBL] [Abstract] [Full Text] [Related]
15. Target of rapamycin signaling in leukemia and lymphoma.
Vu C; Fruman DA
Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
[TBL] [Abstract] [Full Text] [Related]
16. Involvement of TORC2, a CREB co-activator, in the in vivo-specific transcriptional control of HTLV-1.
Jiang S; Inada T; Tanaka M; Furuta RA; Shingu K; Fujisawa J
Retrovirology; 2009 Aug; 6():73. PubMed ID: 19664292
[TBL] [Abstract] [Full Text] [Related]
17. IL-2- and IL-15-induced activation of the rapamycin-sensitive mtorc1 pathway in malignant CD4+ T lymphocytes.
Marzec M; Liu X; Kasprzycka M; Witkiewicz A; Raghunath PN; El-Salem M; Robertson E; Odum N; Wasik MA
Blood; 2008 Feb; 111(4):2181-9. PubMed ID: 18025151
[TBL] [Abstract] [Full Text] [Related]
18. Advances in salivary gland pathology.
Cheuk W; Chan JK
Histopathology; 2007 Jul; 51(1):1-20. PubMed ID: 17539914
[TBL] [Abstract] [Full Text] [Related]
